Guy, J., Cheval, H., Selfridge, J. & Bird, A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27, 631–652 (2011).
Chao, H. T. & Zoghbi, H. Y. MeCP2: only 100% will do. Nat. Neurosci. 15, 176–177 (2012).
Leonard, H., Cobb, S. & Downs, J. Clinical and biological progress over 50 years in Rett syndrome. Nat. Rev. Neurol. 13, 37–51 (2017).
Van Esch, H. et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 77, 442–453 (2005).
Lugtenberg, D. et al. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur. J. Hum. Genet. 17, 444–453 (2009).
Takeguchi, R. et al. Early diagnosis of MECP2 duplication syndrome: insights from a nationwide survey in Japan. J. Neurol. Sci. 422, 117321 (2021).
Pascual-Alonso, A., Martinez-Monseny, A. F., Xiol, C. & Armstrong, J. MECP2-related disorders in males. Int. J. Mol. Sci. 22, 9610 (2021).
Shahbazian, M. D. & Zoghbi, H. Y. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am. J. Hum. Genet. 71, 1259–1272 (2002).
Ramocki, M. B. & Zoghbi, H. Y. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature 455, 912–918 (2008).
Nageshappa, S. et al. Altered neuronal network and rescue in a human MECP2 duplication model. Mol. Psychiatry 21, 178–188 (2016).
Marafi, D. et al. Spectrum and time course of epilepsy and the associated cognitive decline in MECP2 duplication syndrome. Neurology 92, e108–e114 (2019).
Ak, M. et al. Assessing the burden on caregivers of MECP2 duplication syndrome. Pediatr. Neurol. 133, 1–8 (2022).
Peters, S. U. et al. Phenotypic features in MECP2 duplication syndrome: effects of age. Am. J. Med. Genet. A 185, 362–369 (2021).
Shao, Y. et al. Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome. Sci. Transl. Med. 13, eaaz7785 (2021).
Sztainberg, Y. et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. Nature 528, 123–126 (2015).
Yu, B. et al. Reversal of social recognition deficit in adult mice with MECP2 duplication via normalization of MeCP2 in the medial prefrontal cortex. Neurosci. Bull. 36, 570–584 (2020).
Xu, C. et al. Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat. Methods 18, 499–506 (2021).
Kannan, S. et al. Compact RNA editors with small Cas13 proteins. Nat. Biotechnol. 40, 194–197 (2021).
Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. 41, 108–119 (2023).
Pacheco, N. L. et al. RNA sequencing and proteomics approaches reveal novel deficits in the cortex of Mecp2-deficient mice, a model for Rett syndrome. Mol. Autism 8, 56 (2017).
Brito, D. V. C., Gulmez Karaca, K., Kupke, J., Frank, L. & Oliveira, A. M. M. MeCP2 gates spatial learning-induced alternative splicing events in the mouse hippocampus. Mol. Brain 13, 156 (2020).
Renthal, W. et al. Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing. Nat. Neurosci. 21, 1670–1679 (2018).
Gogliotti, R. G. et al. Total RNA sequencing of Rett syndrome autopsy samples identifies the M4 muscarinic receptor as a novel therapeutic target. J. Pharmacol. Exp. Ther. 365, 291–300 (2018).
Heckman, L. D., Chahrour, M. H. & Zoghbi, H. Y. Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice. eLife 3, e02676 (2014).
Collins, A. L. et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679–2689 (2004).
Ramocki, M. B., Tavyev, Y. J. & Peters, S. U. The MECP2 duplication syndrome. Am. J. Med. Genet. A 152A, 1079–1088 (2010).
Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224–1229 (2008).
Morikawa, M., Derynck, R. & Miyazono, K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 8, a021873 (2016).
Bajikar, S. S. et al. MeCP2 regulates Gdf11, a dosage-sensitive gene critical for neurological function. eLife 12, e83806 (2023).
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379–414 (2019).
Torregrosa, T. et al. Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice. Gene Ther. 28, 456–468 (2021).
Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102–106 (2015).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41593-024-01838-6